Literature DB >> 9060649

Coexistence in lactate dehydrogenase-elevating virus pools of variants that differ in neuropathogenicity and ability to establish a persistent infection.

Z Chen1, R R Rowland, G W Anderson, G A Palmer, P G Plagemann.   

Abstract

Neuropathogenic isolates of lactate dehydrogenase-elevating virus (LDV) differ from nonneuropathogenic isolates in their unique ability to infect anterior horn neurons of immunosuppressed C58 and AKR mice and cause paralytic disease (age-dependent poliomyelitis [ADPM]). However, we and others have found that neuropathogenic LDVs fail to retain their neuropathogenicity during persistent infections of both ADPM-susceptible and nonsusceptible mice. On the basis of a segment in open reading frame 2 that differs about 60% between the neuropathogenic LDV-C and the nonneuropathogenic LDV-P, we have developed a reverse transcription-PCR assay that distinguishes between the genomes of the two LDVs and detects as little as 10 50% infectious doses (ID50) of LDV. With this assay, we found that LDV-P and LDV-C coexist in most available pools of LDV-C and LDV-P. For example, various plasma pools of 10(9.5) ID50 of LDV-C/ml contained about 10(5) ID50 of LDV-P/ml. Injection of such an LDV-C pool into mice of various strains resulted in the rapid displacement in the circulation of LDV-C by LDV-P as the predominant LDV, but LDV-C also persisted in the mice at a low level along with LDV-P. We have freed LDV-C of LDV-P by endpoint dilution (LDV-C-EPD). LDV-C-EPD infected mice as efficiently as did LDV-P, but its level of viremia during the persistent phase was only 1/10,000 that observed for LDV-P. LDV-permissive macrophages accumulated and supported the efficient replication of superinfecting LDV-P. Therefore, although neuropathogenic LDVs possess the unique ability to infect anterior horn neurons of ADPM-susceptible mice, they exhibit a reduced ability to establish a persistent infection in peripheral tissues of mice regardless of the strain. The specific suppression of LDV-C replication in persistently infected mice is probably due in part to a more efficient neutralization of LDV-C than LDV-P by antibodies to the primary envelope glycoprotein, VP-3P. Both neuropathogenicity and the higher sensitivity to antibody neutralization correlated with the absence of two of three N-linked polylactosaminoglycan chains on the ca. 30-amino-acid ectodomain of VP-3P, which seems to carry the neutralization epitope(s) and forms part of the virus receptor attachment site.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9060649      PMCID: PMC191418     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  C58 and AKR mice of all ages develop motor neuron disease after lactate dehydrogenase-elevating virus infection but only if antiviral immune responses are blocked by chemical or genetic means or as a result of old age.

Authors:  G W Anderson; C Even; R R Rowland; G A Palmer; J T Harty; P G Plagemann
Journal:  J Neurovirol       Date:  1995-09       Impact factor: 2.643

2.  Definition and identification of homology domains.

Authors:  C B Lawrence; D A Goldman
Journal:  Comput Appl Biosci       Date:  1988-03

3.  Age-dependent paralytic viral infection in C58 mice: possible implications in human neurologic disease.

Authors:  W H Murphy; J F Nawrocki; L R Pease
Journal:  Prog Brain Res       Date:  1983       Impact factor: 2.453

4.  Etiologic role of lactic dehydrogenase virus infection in an age-dependent neuroparalytic disease in C58 mice.

Authors:  J F Nawrocki; L R Pease; W H Murphy
Journal:  Virology       Date:  1980-05       Impact factor: 3.616

5.  Antibody response of mice to lactate dehydrogenase-elevating virus during infection and immunization with inactivated virus.

Authors:  W A Cafruny; S P Chan; J T Harty; S Yousefi; K Kowalchyk; D McDonald; B Foreman; G Budweg; P G Plagemann
Journal:  Virus Res       Date:  1986-09       Impact factor: 3.303

6.  Cell surface receptors for lactate dehydrogenase-elevating virus on subpopulation of macrophages.

Authors:  K Kowalchyk; P G Plagemann
Journal:  Virus Res       Date:  1985-04       Impact factor: 3.303

7.  Structure and chemical-physical characteristics of lactate dehydrogenase-elevating virus and its RNA.

Authors:  M Brinton-Darnell; P G Plagemann
Journal:  J Virol       Date:  1975-08       Impact factor: 5.103

8.  Mouse strain-specific central nervous system lesions associated with lactate dehydrogenase-elevating virus infection.

Authors:  W G Stroop; M A Brinton
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

9.  Replication of lactate dehydrogenase-elevating virus in C58 mice and quantification of antiviral antibodies and of tissue virus levels as a function of development of paralytic disease.

Authors:  W A Cafruny; C R Strancke; K Kowalchyk; P G Plagemann
Journal:  J Gen Virol       Date:  1986-01       Impact factor: 3.891

10.  Identification of lactate dehydrogenase-elevating virus as the etiological agent of genetically restricted, age-dependent polioencephalomyelitis of mice.

Authors:  D Martinez; M A Brinton; T G Tachovsky; A H Phelps
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

View more
  5 in total

1.  Heterodimerization of the two major envelope proteins is essential for arterivirus infectivity.

Authors:  Eric J Snijder; Jessika C Dobbe; Willy J M Spaan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants.

Authors:  Dominique Markine-Goriaynoff; Jean-Paul Coutelier
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Poliomyelitis in MuLV-infected ICR-SCID mice after injection of basement membrane matrix contaminated with lactate dehydrogenase-elevating virus.

Authors:  Jodi A Carlson Scholz; Rohit Garg; Susan R Compton; Heather G Allore; Caroline J Zeiss; Edward M Uchio
Journal:  Comp Med       Date:  2011-10       Impact factor: 0.982

4.  Different clinical, virological, serological and tissue tropism outcomes of two new and one old Belgian type 1 subtype 1 porcine reproductive and respiratory virus (PRRSV) isolates.

Authors:  Ilias S Frydas; Ivan Trus; Lise K Kvisgaard; Caroline Bonckaert; Vishwanatha R A P Reddy; Yewei Li; Lars E Larsen; Hans J Nauwynck
Journal:  Vet Res       Date:  2015-03-21       Impact factor: 3.683

Review 5.  Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development.

Authors:  X J Meng
Journal:  Vet Microbiol       Date:  2000-06-12       Impact factor: 3.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.